Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept
Clinical Immunology · 2024-07 · 264 · 110240
DOI: 10.1016/j.clim.2024.110240 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Immunology, 2024-07. Verfasst von Evaldo Favi und 13 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery and Kidney Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; Department of Clinical Sci…. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Monoclonal, Humanized, Graft Rejection. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health.
Abstract (Originalsprache)
Kidney transplant (KT) candidates with donor-specific antibodies (DSA) exhibit exceedingly high antibody-mediated rejection (ABMR) and allograft loss rates. Currently, treatment of ABMR remains an unmet clinical need. We report the use of the anti-C5 eculizumab and the type-2 anti-CD20 obinutuzumab in two patients with early ABMR. Eculizumab (900 mg IV) led to complete inhibition of the terminal complement cascade (unremarkable AP50 and CH50 activity) and prompt stoppage of complement-dependent antibody-mediated allograft injury (clearance of intra-graft C4d and C5b-9 deposition). Despite complement inhibition, obinutuzumab (1000 mg IV) determined full and long-lasting peripheral B-cell depletion, with significant reduction in all DSA. Graft function improved, remaining stable up to three years of follow-up. No signs of active ABMR and rebound DSA were detected. Obinutuzumab B-cell depletion and inhibition of DSA production were not affected by complement blockage. Further studies are needed to confirm the potential benefit of obinutuzumab in association with complement inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery and Kidney Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano, 20122 Mi…
- Nephrology, Dialysis and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- General Surgery and Kidney Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Renal Research Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Pediatric Nephrology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Laboratorio di Immunologia dei Trapianti, Trapianti Lombardia - NITp, 20122 Milan, Italy.
Förderung
- Ministry of Health
Zitieren
APA
Favi, E., Cresseri, D., Perego, M., Ikehata, M., Iesari, S., Campise, M. R., Morello, W., Testa, S., Sioli, V., Mattinzoli, D., Longhi, E., Del Gobbo, A., Castellano, G., & Ferraresso, M. (2024). Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept. Clinical Immunology, 264, 110240. https://doi.org/10.1016/j.clim.2024.110240
Vancouver
Favi E, Cresseri D, Perego M, Ikehata M, Iesari S, Campise MR, et al. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept. Clinical Immunology. 2024;264:110240. doi:10.1016/j.clim.2024.110240
BibTeX
@article{Favi2024,
author = {Favi, Evaldo and Cresseri, Donata and Perego, Marta and Ikehata, Masami and Iesari, Samuele and Campise, Maria Rosaria and Morello, William and Testa, Sara and Sioli, Viviana and Mattinzoli, Deborah and Longhi, Elena and Del Gobbo, Alessandro and Castellano, Giuseppe and Ferraresso, Mariano},
title = {Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept},
journal = {Clinical Immunology},
year = {2024},
volume = {264},
pages = {110240},
doi = {10.1016/j.clim.2024.110240}
}
EUVIMED